Landos Biopharma, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Landos Biopharma, Inc. | LABP - NASDAQ |
$15.00-$17.00 | $16.00 | $13.00 | 6.25 million | 2/4/2021 |
| JP Morgan, Jefferies, SVB Leerink | ||||||
Co-Manager(s): Raymond James | ||||||
| Health Care | ||||||
Filing(s): Filed 2021-01-13 Terms Added 2021-01-28 | ||||||
Landos Biopharma, Inc. Quote & Chart - Click for current quote - LABP
IPO Boutique aggregates information on public companies and private companies, such as "LABP" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Landos Biopharma, Inc. (adapted from Landos Biopharma, Inc. prospectus):
They are a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases that are the first to target new mechanisms of action, including the LANCL2, NLRX1 and PLXDC2 immunometabolic pathways.according to the CIC report.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases that are the first to target new mechanisms of action, including the LANCL2, NLRX1 and PLXDC2 immunometabolic pathways.according to the CIC report.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "LABP" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.